OCULIS HOLDING AG (OCS) Stock Price, Forecast & Analysis
NASDAQ:OCS • CH1242303498
OCS Key Statistics, Chart & Performance
The current stock price of OCS is 28.49 USD. In the past month the price increased by 5.52%. In the past year, price increased by 46.32%.
OCS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OCS. When comparing the yearly performance of all stocks, OCS is one of the better performing stocks in the market, outperforming 91.78% of all stocks.
OCS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCS. While OCS seems to be doing ok healthwise, there are quite some concerns on its profitability.
OCS Financial Highlights
Over the last trailing twelve months OCS reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS decreased by -22.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.02% | ||
| ROE | -79.71% | ||
| Debt/Equity | 0.02 |
OCS Forecast & Estimates
15 analysts have analysed OCS and the average price target is 44.88 USD. This implies a price increase of 57.53% is expected in the next year compared to the current price of 28.49.
For the next year, analysts expect an EPS growth of 10.85% and a revenue growth -17.65% for OCS
OCS Ownership
OCS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.47 | 1.001T | ||
| JNJ | JOHNSON & JOHNSON | 21.15 | 592.302B | ||
| MRK | MERCK & CO. INC. | 22.94 | 307.324B | ||
| PFE | PFIZER INC | 9.09 | 153.855B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 124.69B | ||
| ZTS | ZOETIS INC | 18.67 | 55.434B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.78 | 26.247B | ||
| VTRS | VIATRIS INC | 6.49 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.36 | 12.297B | ||
| AXSM | AXSOME THERAPEUTICS INC | 206.78 | 8.81B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCS
Company Profile
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Company Info
OCULIS HOLDING AG
Bahnhofstrasse 20
Zug ZUG CH
Employees: 49
Phone: 41417113960
OCULIS HOLDING AG / OCS FAQ
Can you describe the business of OCULIS HOLDING AG?
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Can you provide the latest stock price for OCULIS HOLDING AG?
The current stock price of OCS is 28.49 USD. The price decreased by -0.56% in the last trading session.
What is the dividend status of OCULIS HOLDING AG?
OCS does not pay a dividend.
How is the ChartMill rating for OCULIS HOLDING AG?
OCS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is OCS stock listed?
OCS stock is listed on the Nasdaq exchange.
What is OCULIS HOLDING AG worth?
OCULIS HOLDING AG (OCS) has a market capitalization of 1.65B USD. This makes OCS a Small Cap stock.
Who owns OCULIS HOLDING AG?
You can find the ownership structure of OCULIS HOLDING AG (OCS) on the Ownership tab.